TY - JOUR T1 - Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives JF - Lupus Science & Medicine JO - Lupus Sci Med DO - 10.1136/lupus-2022-000776 VL - 10 IS - 1 SP - e000776 AU - Eya Toumi AU - Soraya Mezouar AU - Anne Plauzolles AU - Laurent Chiche AU - Nathalie Bardin AU - Philippe Halfon AU - Jean Louis Mege Y1 - 2023/02/01 UR - http://lupus.bmj.com/content/10/1/e000776.abstract N2 - Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome. ER -